The issues that brought this study to a halt echo the types of vaginal mesh complications many of our own clients have allegedly suffered.
New York, NY (PRWEB) September 13, 2013
As transvaginal mesh lawsuits (http://www.filevaginalmeshlawsuit.com/) continue to move forward in courts around the country, Bernstein Liebhard LLP notes that a new study has found that the use of vaginal mesh in pelvic prolapse repair does not appear to be associated with improved cure rates compared to traditional non-mesh procedures. The study, which was published on September 9th in the journal, Obstetrics & Gynecology, found no difference in the three-year cure rates between the two groups. However, the research was halted early due to a mesh exposure rate of more than 15%. Three women in the mesh group also required revision surgery for recurrent prolapse, while none in the non-mesh group experienced this complication. The study followed 65 women, 33 of whom received vaginal mesh, with the remainder undergoing a non-mesh procedure.*
“The issues that brought this study to a halt echo the types of vaginal mesh complications many of our own clients have allegedly suffered. Its results also confirm that the use of vaginal mesh in pelvic organ prolapse repair may carry substantial risks compared to alternate procedures, without offering patients any additional benefits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently representing hundreds of women in vaginal mesh lawsuits who suffered mesh erosion, pain, scarring, infection and other serious injuries, allegedly due to transvaginal mesh products marketed by American Medical Systems, Inc., Boston Scientific, Inc., C.R. Bard and Ethicon, Inc.
Vaginal Mesh Lawsuits
Transvaginal mesh has been the subject of growing safety concerns since October 2008, when the U.S. Food & Drug Administration (FDA) revealed that it had received more than 1,000 reports of injuries associated with the devices over a three year period. In July 2011, the FDA issued another warning after the reports of serious complications associated with the use of transvaginal mesh in pelvic organ prolapse repair increased by five-fold. The agency also modified the position it had taken in 2008 regarding frequency of vaginal mesh complications in prolapse repair, stating in the alert that these injuries were not rare.
Court documents indicate that more than 20,000 vaginal mesh lawsuits are pending in federal multidistrict litigations now underway in U.S. District Court, Southern District of West Virginia, all of which allege serious injuries due to the use of transvaginal mesh. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committee in four of those litigations, including: In re: American Medical Systems, Inc., Pelvic Repair Systems Products Liability Litigation - MDL No. 2325; In re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation - MDL No. 2326; In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, MDL No. 2187; and In re: Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation - MDL No. 2327.
On August 15th, the federal litigation’s first trial of a transvaginal mesh lawsuit concluded when a woman injured by a by C.R. Bard’s Avaulta Plus device was awarded $2 million. (Cisson v. C.R. Bard Inc., 11-cv-00195) The litigation’s second C.R. Bard trial was to get underway the following week, but an undisclosed settlement was reached in the case just prior to the start of opening arguments. (Queen v. C.R. Bard Inc., 11-cv-00012)
Thousands of vaginal mesh lawsuits filed on behalf of women who were allegedly injured by products marketed by C.R. Bard and Ethicon are also pending in two consolidated litigations underway in New Jersey’s Atlantic County Superior Court. Mr. Grand serves as Co-Liaison Counsel in both of those proceedings, and was also a member of the trial team on the litigation’s first Ethicon trial. That case ended in March with an $11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10).
Alleged victims of vaginal mesh complications may be entitled to compensation for their medical bills, lost wages, pain and suffering and other damages. Learn more about transvaginal mesh complications on Bernstein Liebhard LLP's website. Free legal reviews can also be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP